Optimising post-approval research: using technology for efficient and cost-effective studies

A large global Pharma company was required to run a complex global safety study by regulatory authorities. This was a crucial study to ensure that patients were not exposed to risk.

Cisiv was able to build a study in 10 weeks and launch it across 21 countries. Cisiv’s platform – Baseline Plus – was able to deal with complex data capture, analysis and reporting to various licensing authorities.

... to learn more, download the full case study

More Case Studies

  • Real-world studies in complex treatments

    Cisiv’s EDC platform, Baseline Plus, is built specifically to meet the...

  • Designing and conducting a successful HEOR study

    A leading global pharmaceutical company was looking for a...

  • Baseline Plus: Ideally suited for orphan drug post-approval studies

    Baseline Plus provided the ideal platform to enable a specialised...

incisive solutions decisive results

©Cisiv 2021 - All Rights Reserved. Registered Company Number : 3110147

Website by 3Men²